While much earlier in its lifecycle, we have identified that Eli Lilly has filed 53 U.S
Eleven out of 15 studies reported changes in HbA1c, with the most significant reductions observed when compared to placebo
For providers, the availability of these oral options particularly at competitive self-pay price points reinforces the need to position your practices value beyond simply writing a prescription
12 The pharmaceutical industry lobbied for Patent Term Extensions under the Hatch-Waxman Act 1984 to ensure they would be guaranteed up to 14 years of market protection from the date of a products approval
This was interesting because at that time it was assumed that the best way to treat patients with metabolic disorders was not to stimulate more glucagon because it raises blood sugar, but instead to block it
For patients with obesity-related comorbidities such as hypertension, dyslipidaemia, or fatty liver disease these combined effects could represent a clinically meaningful advance if confirmed in Phase 3 data
)
